Tamoxifen (TAM), one of the oldest and most frequently utilized SERMs, is now typically prescribed to treat hormone receptor-positive, early-stage breast cancer after surgery to reduce disease recurrence in pre-menopausal women [5,18]. The gene discussed is NR4A1; the disease is breast carcinoma.